TCTC Holdings LLC Sells 2,730 Shares of AbbVie Inc. $ABBV

TCTC Holdings LLC trimmed its stake in AbbVie Inc. (NYSE:ABBV) by 2.0% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 135,184 shares of the company’s stock after selling 2,730 shares during the period. AbbVie comprises about 0.9% of TCTC Holdings LLC’s investment portfolio, making the stock its 23rd largest position. TCTC Holdings LLC’s holdings in AbbVie were worth $31,301,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Evolution Wealth Management Inc. bought a new position in AbbVie during the 2nd quarter valued at about $26,000. Spurstone Advisory Services LLC bought a new stake in AbbVie during the second quarter worth about $28,000. Financial Gravity Companies Inc. acquired a new stake in shares of AbbVie during the second quarter worth approximately $36,000. Delos Wealth Advisors LLC bought a new position in shares of AbbVie in the second quarter valued at approximately $39,000. Finally, Abich Financial Wealth Management LLC acquired a new position in shares of AbbVie in the 3rd quarter worth approximately $49,000. 70.23% of the stock is owned by institutional investors.

Trending Headlines about AbbVie

Here are the key news stories impacting AbbVie this week:

• Positive Sentiment: Record sales, earnings beat and firm guidance support outlook — AbbVie reported stronger-than-expected revenue and EPS, posted record net sales and provided FY‑2026 EPS guidance that sits above consensus, all of which underpin near-term revenue visibility and the stock’s rally. AbbVie Achieves Record Net Sales
• Positive Sentiment: Clinical progress — AbbVie advanced a toxin‑based therapy in a Phase 2 ventral hernia trial, which could add a new growth vector if later‑stage data are positive. This is incremental pipeline upside beyond core immunology franchises. Ventral Hernia Trial Update
• Positive Sentiment: Rinvoq real‑world / post‑marketing data — Completion of a Korean post‑market study adds supportive real‑world evidence for Rinvoq adoption in immunology, reinforcing growth expectations in that franchise. Rinvoq Study Wraps Up
• Neutral Sentiment: Investor and conference coverage — Management presented at a Piper Sandler immunology symposium (transcript available); useful for detail on novel targets but no immediate market-moving data were released. Piper Sandler Presentation Transcript
• Negative Sentiment: Medicare pricing legal risk — AbbVie filed suit challenging HHS/CMS’s selection of Botox for Medicare drug‑price negotiations under the Inflation Reduction Act. If Botox remains subject to negotiated price controls, that could materially pressure sales and margins for that product; the lawsuit introduces legal and policy uncertainty. AbbVie Sues US Health Agency
• Negative Sentiment: Analyst pushback — Evercore ISI trimmed its price target modestly (and some firms adjusted expectations), signaling that consensus 2026–27 estimates still face scrutiny despite solid results. That caps some near‑term upside and may limit multiple expansion. Evercore ISI Cuts PT

AbbVie Stock Up 1.8%

Shares of ABBV stock opened at $231.57 on Friday. The firm has a market cap of $409.28 billion, a price-to-earnings ratio of 98.12, a PEG ratio of 0.81 and a beta of 0.35. AbbVie Inc. has a 12 month low of $164.39 and a 12 month high of $244.81. The stock has a 50-day moving average price of $223.56 and a 200 day moving average price of $220.85.

AbbVie (NYSE:ABBV) last released its earnings results on Wednesday, February 4th. The company reported $2.71 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.65 by $0.06. AbbVie had a net margin of 6.91% and a negative return on equity of 4,184.47%. The company had revenue of $16.62 billion for the quarter, compared to the consensus estimate of $16.39 billion. During the same period in the prior year, the company posted $2.16 EPS. The company’s revenue was up 10.0% compared to the same quarter last year. AbbVie has set its FY 2026 guidance at 14.370-14.570 EPS and its Q1 2026 guidance at 2.970-3.010 EPS. Sell-side analysts predict that AbbVie Inc. will post 12.31 earnings per share for the current fiscal year.

Analyst Ratings Changes

ABBV has been the subject of a number of recent analyst reports. UBS Group dropped their price target on AbbVie from $240.00 to $230.00 and set a “neutral” rating for the company in a report on Thursday, February 5th. Raymond James Financial set a $256.00 target price on AbbVie in a report on Monday, November 3rd. Guggenheim lifted their price target on AbbVie from $227.00 to $242.00 and gave the company a “buy” rating in a report on Monday, October 20th. Citigroup decreased their price objective on shares of AbbVie from $235.00 to $230.00 and set a “neutral” rating on the stock in a report on Tuesday, January 27th. Finally, JPMorgan Chase & Co. raised their price objective on shares of AbbVie from $250.00 to $260.00 and gave the company an “overweight” rating in a research report on Monday, November 3rd. Two analysts have rated the stock with a Strong Buy rating, eleven have assigned a Buy rating and nine have assigned a Hold rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Moderate Buy” and an average price target of $251.00.

AbbVie Company Profile

AbbVie is a global, research-driven biopharmaceutical company that was created as a spin-off from Abbott Laboratories in 2013 and is headquartered in North Chicago, Illinois. The company focuses on discovering, developing and commercializing therapies for complex and often chronic medical conditions. Its operations span research and development, manufacturing, regulatory affairs and commercialization, with an emphasis on bringing specialty medicines to market across multiple therapeutic areas.

AbbVie’s product portfolio and pipeline cover several major therapeutic categories, including immunology, oncology, neuroscience, virology and women’s health.